G.Z. Mukhametshina1,2, R.Sh. Khasanov1, S.V. Petrov2,3, L.G. Karpenko1, M.N. Shabalina1
1Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan
2Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Kazan
3Kazan State Medical University, Kazan
Mukhametshina Guzel Z. ― Cand. of Sci. (Med.), associate professor of the department of oncology, radiology and palliative medicine of the Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, oncologist of the department of chemotherapy №1 of the Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal
29 Sibirskiy Tract, Kazan, 420029, Russian Federation, tel. (843) 202-27-20, e-mail: gzm_kazan@mail.ru
Abstract. Hyperexpression of HER2 in metastatic solid tumors is a promising application point for targeted therapy. Based on the studied mechanism of action and long-term experience with anti-HER2 therapy for breast cancer, allows us to hope for a similar effect in malignant diseases of other localizations. By analogy with breast cancer, it can be assumed that the expression of HER2 in solid tumors may be associated with a poor prognosis and a worse response to cytostatic therapy. Additional treatment lines with anti-HER2 may improve the long-term outcome if the hyperexpression or amplification of HER2 is detected.
Key words: targeted therapy, HER2, solid tumors.